Myocardial Transfection of Hypoxia Inducible Factor-1.ALPHA. via an Adenoviral Vector During Coronary Artery Bypass Grafting - A Multicenter Phase I and Safety Study -

• Kilian Eckehard Gerd

  Department of Cardiac Surgery, University of Munich

• Sadoni Sebastian

  Department of Cardiac Surgery, University of Munich

• Vicol Calin

  Department of Cardiac Surgery, University of Munich

• Kelly Ralph

  Genzyme, Europe BV

• Hulst Karen van

  Genzyme, Europe BV

• Schwaiger Markus

  Department of Nuclear Medicine, University of Munich

• Kupatt Christian

  Department of Cardiology, University of Munich

• Boekstegers Peter

  Department of Cardiology, University of Munich

• Pillai Ravi

  Department of Cardiothoracic Surgery, John Radcliffe Hospital

• Channon Keith

  Department of Cardiovascular Medicine, John Radcliffe Hospital

• Hetzer Roland

  German Heart Centre Berlin, Department of Cardiothoracic and Vascular Surgery

• Reichart Bruno

  Department of Cardiac Surgery, University of Munich

書誌事項

タイトル別名

• – A Multicenter Phase I and Safety Study –

抄録

Background: Increasing numbers of patients with advanced coronary artery disease have limited options for percutaneous and/or surgical revascularization. A prospective, randomized, phase I clinical multicenter trial was performed to assess the feasibility and safety of delivering a pro-angiogenic transcription factor termed "hypoxia inducible factor-1α", delivered to ischemic cardiac muscle via a type 2 adenoviral (Ad2HIF) vector. Methods and Results: The 13 patients were included under the following criteria: 1 hypoperfused area of viable ventricular muscle without options for revascularization and left ventricular ejection fraction ≥30%. After coronary artery bypass grafting was completed, 10 injections of the study drug (n=10), in 3 escalating doses up to 1×10¹¹ viral particles or saline (n=3) as a placebo control, were injected intramyocardially. After completion of the 1-year follow-up, all patients had uncomplicated postoperative courses, are alive and feeling well; 1 patient had a self-limited run of tachycardia postoperatively and at 6 months, 1 patient developed recurrent angina. Positron emission tomography perfusion analysis revealed improvement in the Ad2HIF injected areas in selected patients. Conclusions: These data support the feasibility and preliminary safety of adenoviral transfection with Ad2HIF in regions of viable myocardium. Additional studies will be required to determine the efficacy and safety of Ad2HIF. (Circ J 2010; 74: 916 - 924)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 74 (5), 916-924, 2010

  一般社団法人 日本循環器学会

キーワード

• Aortocoronary bypass
• Coronary angiogenesis
• HIF-1α
• Viral transfection

詳細情報

• CRID: 1390001205102806272
• NII論文ID: 10026473576
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-09-0594
• ISSN: 13474820
• ISSN: 13469843
• Web Site: http://www.jstage.jst.go.jp/article/circj/74/5/74_CJ-09-0594/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2010265646
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可